It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...
Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...
The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. In recent years, these two healthcare leaders have also been butting heads in the GLP-1 weight loss space. Eli Lilly's ...
Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the ...
Over half of American adults are eligible for semaglutide, but insurance and other barriers make it hard for people to access ...
On its own, obesity can cause acute ailments, including breathlessness and back pain. Worse, it often leads to other chronic ...
Part of the joy of the season may be gone — or feel different — for people who are taking popular weight-loss drugs and can't ...
Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...
As new research suggests those taking GLP-1 drugs have fewer hospitalisations for alcoholism, a leading specialist warns ...
Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...